Esco Micro Pte. Ltd., manufacturer of some of the most innovative life science tools, has successfully raised a Series A investment of USD 200 million from a club of investors, including Vivo Capital, Novo Holdings, China Investment Corporation, K3 Ventures, and EDBI Singapore. This financing – the largest private fundraising round by an Asia-based life sciences tools company – will, amongst other things, enable Esco Micro to create an innovation hub focused on cell and gene therapy tools and technologies.
The Spice Route Legal team – comprising of Mathew Chacko, Shivam Anand, Priya Venkatesan, and Preethika Nannapaneni – acted as India counsel to the investee company. Davis Polk Waldwell acted as lead counsel to the investor.